We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00197431
Recruitment Status : Unknown
Verified December 2003 by Hamamatsu University.
Recruitment status was:  Recruiting
First Posted : September 20, 2005
Last Update Posted : March 22, 2006
Sponsor:
Information provided by:

September 12, 2005
September 20, 2005
March 22, 2006
January 2004
Not Provided
Whether the differences in activities of CYP2A6 and DPD affect pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes
Whether the differences in activities of CYP2A6 and DPD effect on pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes.
Complete list of historical versions of study NCT00197431 on ClinicalTrials.gov Archive Site
Side effect and motility of patients treated with S-1
Side effect and motility of patients who treated with S-1.
Not Provided
Not Provided
 
Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
Pharmacokinetic and Pharmacodynamic Study of S-1 and Its Effects in Patients With the Digestive Organ Cancer With Reference to Genetic Polymorphism and Activity of CYP2A6 and DPD
S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydropyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. 5-FU is metabolized by CYP2A6 and DPD. In this study, the researchers investigate the influences of differences in activities of CYP2A6 and DPD on pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes in digestive organ cancer patients treated with S-1.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Gastric Cancer
  • Esophageal Cancer
  • Pancreatic Cancer
  • Colon Cancer
Drug: S-1
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with digestive organ cancer

Exclusion Criteria:

  • Patients without digestive organ cancer
Sexes Eligible for Study: All
20 Years to 85 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00197431
S-12005
Not Provided
Not Provided
Not Provided
Not Provided
Hamamatsu University
Not Provided
Study Chair: Naohito Shirai, MD., PhD Department Laboratory Medicine, Hamamatsu University School of Medicine
Hamamatsu University
December 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP